Soon after Sanofi closed its $20 billion deal to buy Genzyme, CEO Chris Viehbacher (photo) made it clear that the storied biotech company would remain a standalone entity, reassuring loyalists by retaining its name and pushing ahead on its R&D efforts. Now the Boston Globe reports that only a scaled-down version of Genzyme will remain semi-independent as Sanofi absorbs the rest of the company. Report